MedTrace Logo

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 710

Last updated 2026-05-04

No results posted yet for this study

Summary

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

Conditions

Interventions

DRUG

INCB161734

INCB161734 will be administered at protocol defined dose.

DRUG

Cetuximab

Cetuximab will be administered at protocol defined dose.

DRUG

Retifanlimab

Retifanlimab will be administered at protocol defined dose.

DRUG

GEMNabP

GEMNabP will be administered at protocol defined dose.

DRUG

mFOLFIRINOX

mFOLFIRINOX will be administered at protocol defined dose.

DRUG

FOLFOX

FOLFOX will be administered at protocol defined dose.

DRUG

FOLFIRI

FOLFIRI will be administered at protocol defined dose.

DRUG

INCA33890

INCA33890 will be administered at protocol defined dose.

Sponsors & Collaborators

Principal Investigators

  • Incyte Medical Monitor · Incyte Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-04
Primary Completion
2027-01-01
Completion
2027-01-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • France
  • Italy
  • Japan
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06179160 on ClinicalTrials.gov